Open AccessThe place of combination of lercanidipine – enalapril in the treatment of hypertension: efficacy, safety, special features
Author(s) -
O. М. Barna
Publication year - 2021
Publication title -
lìki ukraïni
Language(s) - English
Resource type - Journals
ISSN - 1997-9894
DOI - 10.37987/1997-9894.2021.1(247).226315
Subject(s) - enalapril , lercanidipine , medicine , blood pressure , concomitant , combination therapy , fixed dose combination , cardiology , intensive care medicine , angiotensin converting enzyme
In order to improve the effectiveness of antihypertensive treatment, doctors more often prescribe fixed dose combinations of two or three antihypertensive products. In this case, the concomitant effects of these products contribute to better control of blood pressure, improve patient’s adherence to treatment and reduce the risk of side effects. The fixed dose combination of lercanidipine and enalapril is quite new for Ukrainian physicians; however, there is already a sufficient evidence base for the efficacy and safety of such combination therapy. Lecranidipine – enalapril combination reduce systolic and diastolic blood pressure in patients with moderate hypertension without severe side effects. In addition, this combination is effective and safe in patients with comorbidities.